PHILADELPHIA–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/BIO2019?src=hash” target=”_blank”gt;#BIO2019lt;/agt;–The 2019 BIO International Convention runs June 3 – 6, 2019 at the
Pennsylvania Convention Center in Philadelphia, PA.
Business Wire is the official
news distribution partner for BIO 2019. Exhibitor profiles from
the convention are listed below.
Acumen Analytics is an information management and analytics
AlloMek strives to develop innovative therapeutics to patients with
rare and debilitating diseases. Targeting orphan diseases using
AlloMek was formed to develop, and out-license, a novel class of MEK
inhibitors represented by the lead compound CIP-137401.
CIP-1374 was discovered by Cheminpharma, LLC team. All intellectual
property and rights related to CIP-1374 were transferred from
Cheminpharma to AlloMek Therapeutics.
|Company:||Amarex Clinical Research|
Amarex is a CRO headquartered in Maryland (USA) providing complete,
worldwide clinical product safety & efficacy testing and FDA
regulatory services. Amarex helps companies from the pre-clinical
stage through the marketing approval application. Our custom
regulatory approval plan serves to guide efficient pre-clinical and
clinical testing and is helpful for fund raising.
If your management is new to the regulatory approval process, Amarex
can guide you through to success, serving as your virtual Clinical,
Medical Safety, Biometrics, and Regulatory departments to create and
execute the regulatory approval plan.
|Company:||American Gene Technologies|
AGT is a gene and cell therapy company with a gene-delivery platform
designed to rapidly develop cures to infectious diseases, cancers,
and monogenic disorders. AGT’s mission is to transform people’s
lives through genetic medicines that rid the body of disease. AGT’s
lead candidate for an HIV cure is expected to enter the clinic in
2019. In parallel, AGT has a patented immuno-oncology approach to
stimulate the body’s immune system to destroy solid tumors. AGT has
also developed a synthetic gene it expects to cure Phenylketonuria
(PKU) which is anticipated to reach the clinic in 2020.
|Company:||American Laboratory Trading|
American Laboratory Trading, a BIO Business Solutions® provider and
Agilent Channel Partner, specializes in Asset Recovery, Refurbish
and Resale services of secondary lab equipment in the life sciences
Our asset recovery program goes beyond a ‘one-size-fits-all’
approach. Whether you need to monetize one instrument, liquidate an
entire lab or require ongoing program management, we can help.
Our refurbish and resale services offer our customers a lower point
of entry to high-quality, brand name instrumentation. We carry more
than 12,000 instruments in-stock, ranging from benchtop accessories
to triple quad mass spectrometers.
|Learn more at www.ALT.bio.|
Ardigen is a life science computational partner in the era of
Artificial Intelligence. We provide comprehensive technology and
custom services that leverage our domain knowledge and expertise in
bioinformatics, machine learning and software engineering together
with our proprietary technology. Ardigen platforms for neoepitope,
biomarker, and microbiome research facilitate the improvement of the
response rates in immuno-oncology.
|Company:||Asta Pharmaceuticals Co., Ltd.|
We are a privately held company based in Toyama, Japan with
|Company:||Avacta Life Sciences|
|Ticker Symbol & Exchange:||AVCT:LON|
At Avacta Life Sciences, our mission is to create a high quality,
powerful set of tools to help Life Scientists accelerate the
understanding of biology and disease and to help them apply these
advances to diagnosis and treatment. Affimer® reagents are
engineered affinity proteins that are set to revolutionise the
reagents market. They are based on a small protein scaffold that can
be engineered to bind with high specificity and affinity to a wide
range of protein targets. With a ground-breaking rapid custom
service and a growing online catalogue, Affimer reagents can be used
for a wide range of applications in diagnostics, drug/biomarker
discovery, biotech research & development and as therapeutic agents.
|Company:||Axiom Real-Time Metrics|
Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful
and cost-effective eClinical solutions and services focused around
small to medium biotech, medical device and CROs. Services include:
Data Management, Data Analytics, Biostatistics and
Pharmacovigilance. Axiom’s eClinical suite, Fusion, delivers a
powerful range of innovative end-user focused, unified functionality
and 15 modules. Axiom serves as the Connected Hub for your entire
clinical study data and operational needs. Fusion Delivers: EDC, DM,
IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE
Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7
Project and Clinical Data Reporting.
|For more information, please visit http://www.axiommetrics.com/.|
|Company:||BIO Asia-Taiwan 2019 (Taiwan BIO)|
Co-organized by the global Biotechnology Innovation Organization
(BIO) and the Taiwan Bio Industry Organization (Taiwan BIO), the
inaugural BIO Asia-Taiwan 2019 Conference and Exhibition will be
held in Taipei, Taiwan 24-28 July, 2019. A week-long festival of
biotech-themed conferences, meetings, and presentations, BIO
Asia-Taiwan is poised to become Asia’s most important gathering of
the biotechnology community. Join 1,500 participants from 25
countries at the 3-day conference for sessions on AI for healthcare,
advances in precision medicine, cell and gene therapies, M&A in the
healthcare sector, and more. Participate in BIO One-on-One
Partnering, and take in the latest products and technologies from
more than 600 companies at the four-day exhibition.
BioCT is dedicated to growing the vibrant bioscience ecosystem in
Connecticut by supporting innovation, collaboration, networking,
education, talent engagement and advocacy. We bring together
companies, institutions, entrepreneurs, investors, government,
service providers, and other passionate, dedicated people, to create
a thriving community to improve patients’ lives and public health
and drive economic growth.
A global leader in providing risk reduction solutions, Bioquell’s
wide range of bio-decontamination systems and services help
facilities establish a safe and productive working environment. With
Bioquell’s proprietary and EPA registered 35% Hydrogen Peroxide
Vapor technology, you can eliminate bioburden within lab spaces and
rooms, manufacturing areas, equipment, pass-throughs, and more.
Backed by numerous peer-reviewed studies and trusted around the
world, the process is rapid, effective, and residue-free. Bioquell’s
technology distributes Hydrogen Peroxide Vapor on all exposed
surfaces, providing a 6-log kill. We also offer uniquely designed,
modular isolators integrated with Bioquell bio-decontamination
technology. Visit www.bioquell.com for more information.
|Ticker Symbol & Exchange:||NYSE:BIO|
Bio-Rad is a global leader in developing, manufacturing, and
marketing a broad range of innovative products for the life science
research and clinical diagnostic markets. With a focus on quality
and customer service for over 65 years, our products advance the
discovery process and improve healthcare. Our customers include
university and research institutions, hospitals, biotech and pharma.
Bio-Rad is among the top five life science companies in the world,
providing instruments, software, consumables, reagents, and content
for the areas of cell biology, gene expression, protein
purification, protein quantitation, drug discovery and manufacture,
food safety, and science education.
BioTalent Canada is the HR partner of and a catalyst for growth in
Canada’s bio-economy. Our engagement with employers, associations,
post-secondary institutions, immigrant serving agencies and service
providers has built a dynamic network that is strengthening skills,
connecting job-ready talent to industry and creating opportunities.
Please visit biotalent.ca for more information.
|Company:||Biotech Primer Inc.|
Biotech Primer develops and delivers customized training on the
science and regulatory processes driving the biotechnology,
pharmaceutical, and medical device industries. With continuously
updated materials and industry expert instructors, Biotech Primer
provides the most relevant life science courses worldwide.
|Company:||BRG Regulatory Consulting|
BRG Regulatory Consulting is a full service regulatory and product
development consulting firm. BRG has an excellent reputation as a
leading NDA, 510k, and IND consulting firm, which has clients and
consultants in over 60 countries across the globe. The primary aim
of BRG is to provide efficient and expeditious services and give the
best solutions for our clients’ products that include drugs, medical
devices, biologics, cosmetics, cGMP, quality assurance, and
scientific services. BRG has the expertise you need to increase your
chances of initial FDA approval, saving you both time and resources.
|Company:||Cayman Chemical Company|
Cayman provides pre-clinical discovery and development services to
the global pharmaceutical, biotechnology, and academic research
markets. Our diverse suite of services leverages a team of over 150
highly skilled scientists with expertise in medicinal chemistry,
structure-based drug design, complex multi-step organic synthesis,
analytical chemistry, sample analysis and custom assay development.
We offer a personalized, flexible approach that enables our clients
to accelerate their drug discovery and development through a
single-source partner, from novel drug design and synthesis to
target identification and validation. Visit us at BIO 2019 Exhibitor
|Company:||Celeritas Solutions, LLC|
Celeritas Solutions is a clinical financial management company
|Company:||Cell Microsystems, Inc.|
Cell Microsystems develops, manufactures, and markets innovative
products for single cell research that provide flexibility in
imaging, sorting, and isolation. The CellRaft AIR System and
CytoSort Array enables high-efficiency sorting and isolation of
single cells under standard culture conditions resulting in
unperturbed phenotypes and high viability. A user can select a cell
in real-time and ‘track and trace’ that cell through imaging,
collection and downstream analysis, even for small, precious
samples. The AIR System is uniquely applicable to a broad range of
applications including genomics, cancer research, T-cell screening
in search of immunotherapies, CRISPR gene editing, and stem cell
Clinlogix is a Global Clinical Research Organization working to
improve human quality of life by supporting and accelerating
innovation in the life science industry. Its full suite of clinical
research services supports the regulatory and clinical development
pathway of medical devices, pharmaceuticals, biologics and
diagnostics from proof of concept/discovery, early
feasibility/first-in-human, through pivotal and the
post-marketing/safety surveillance of client products. The company
delivers this global expertise by way of its regional office
locations in the US – Lower Gwynedd, Pennsylvania, Europe – Mainz,
Germany, South America – Medellin, Colombia and Asia – Tokyo, Japan.
Clinvet + Hodei Tech
It is only in the last few years that the Animal Health sector has
We invite you to stop by Booth 4262 (opposite the
CI is Connecticut’s strategic venture capital arm and is the leading
source of financing and ongoing support for innovative, growing
companies. By offering equity investments, strategic guidance and
introductions to valuable partners, we enable promising businesses
|How we help:|
•Investment: Venture capital and strategic support for early-stage
•Connections: Introductions to our vast network of small and big
businesses, talent, university researchers, service providers,
suppliers and more.
•Business Advisers: Mentors who specialize in your sector or the
skills you need, including executives in residence.
CoreRx, a Contract Development Manufacturing Organization (CDMO)
with capabilities to support clinical – niche commercial
manufacturing, offering state of the art facilities to support your
supply chain needs. Our integrated offerings provide comprehensive
services for the development, manufacturing, and testing of solid,
liquid and semi-solid dosage forms.
|Company:||Crowell & Moring LLP|
Crowell & Moring LLP is an international law firm with approximately
550 lawyers representing clients in litigation and arbitration,
regulatory, and transactional matters. Our experienced life sciences
team helps businesses and individuals explore and exploit new
opportunities and markets for their products and ideas, ensure
compliance with regulatory requirements, and resolve disputes
through litigation, mediation, and settlement. Our clients include
individual inventors, research labs, privately owned start-ups,
small to large biotech product and platform companies, and
multinational pharmaceutical, and bioagricultural companies. The
firm has offices in Washington, D.C., New York, Los Angeles, San
Francisco, Orange County, London, and Brussels.
Daicel Corporation, a leader in analysis, manufacturing, and
celebrating 100 years of service to the scientific community, is
expanding its Life Science portfolio to meet the challenges of a
rapidly evolving pharmaceutical industry. Daicel Pharma Services
offers innovative analytical solutions to support timely, safe drug
development with improved cost efficiency. Our GMP facilities are
FDA compliant and offer a full range of analytical method
development, validation, and transfer on formulation products and
drug substances. Daicel Pharma Standards offers a wide range of
high-quality pharmaceutical standards of >95%. Our experienced
chemists employ strict manufacturing protocols to produce effective,
high-purity and high-quality products.
DataArt is a global technology consultancy that designs, develops
and supports unique software solutions, helping clients take their
businesses forward. Recognized for their deep domain expertise and
superior technical talent, DataArt teams create new products and
modernize complex legacy systems that affect technology
transformation in select industries.
DataArt has earned the trust of some of the world’s leading brands
and most discerning clients, including Nasdaq, Travelport, Ocado,
Centrica/Hive, BetfairPaddyPower, IWG, Univision, Meetup and Apple
Leisure Group among others. DataArt brings together expertise of
over 2,800 professionals in 22 locations in the US, Europe, and
DeltaTrak®, Inc., is a leading innovator of food safety and cold
chain management and temperature monitoring solutions.
|Company:||DelveInsight Business Research|
DelveInsight is a Business Consulting and Market research company,
|Company:||Eurofins BioPharma Services|
|Ticker Symbol & Exchange:||ERFSF : Euronext 100|
Eurofins BioPharma Services is a full-service global organization
with dedicated testing facilities for Early Clinical Development,
Central Laboratory Services, Bioanalytical Services, Virology and
Immunology Testing Services, Anatomic Pathology and Genomics
Services. As a division of the Eurofins Scientific Group, our sole
and only focus is clinical laboratory analysis. With €3,781.1
million in annual revenues , over 45,000 employees in 800
laboratories across 47 countries, a portfolio of over 200,000
analytical methods and over 400,000,000 tests performed annually,
Eurofins Scientific is a world leader in laboratory science,
providing a unique range of analytical testing services to the
pharmaceutical, food, environment, and consumer product industries
and to governments.
|Company:||Fina Biosolutions LLC|
Fina Biosolutions LLC (Rockville, MD) is a conjugate vaccine
research and development company. Our mission is to promote
conjugate vaccines. We are a leading provider of conjugate vaccine
technology, including conjugation chemistry, laboratory services and
consulting. Chemistry developed by FinaBio scientists is used in
licensed vaccines world-wide. FinaBio is also a source for
affordable CRM197 vaccine carrier protein. We express CRM197 as a
soluble, properly-folded intracellular protein in E. coli, with high
expression levels and a simple purification process. The protein is
marketed as EcoCRM®. With EcoCRM® and our conjugate vaccine
expertise, we can help turn your antigens into vaccines.
|Company:||G-CON Manufacturing, Inc.|
G-CON Manufacturing designs, builds and installs prefabricated G-CON
POD® cleanrooms. G-CON’s POD portfolio provides cleanrooms in a
number of dimensions for a variety of uses, from laboratory
environments to personalized medicine and production process
platforms. G-CON POD® cleanroom units surpass traditional cleanroom
structures in scalability, mobility and the possibility of
repurposing the PODs once the production process reaches its
|Company:||GVK BIO | Aragen Bioscience|
Established in 2001, GVK BIO is a global Contract Research &
Hesperos Inc. provides insights into novel drug candidates at the
preclinical stage by evaluating their efficacy and safety using
sensitive, functional readouts in human-on-a-chip multi-organ models
to reduce and eventually eliminate use of animal models. This
innovative new technology is helping pharmaceutical researchers,
large and small, make more informed decisions on which drugs to move
forward with, ultimately bringing patients new therapeutics cheaper
and quicker than ever possible before and enabling patient specific
Telepresence: the next best thing to being there.
Hodei’s GEMINI and IKASI Telepresence programs simplify live
Trusted by scientists and medical professionals globally, Hodei
Schedule a meeting or stop by Booth 4262 (opposite the
The International Institute for the Advancement of Medicine (IIAM)
is at the forefront of providing non-transplantable, healthy and
diseased human organs and tissues to the medical research community.
Working with every organ procurement organization in the U.S., IIAM
receives over 15,000 organ referrals for research each year. We
assist with unprecedented collaborations by sourcing livers and
other organs for therapeutic applications and pre-clinical
investigations targeting a multitude of debilitating disorders.
IIAM’s breadth of services also includes a Neonatal Donor Program
that provides neonatal organs and tissues for medical research,
education and development. Please visit our website at www.iiam.org.
We are ILLUSTRATUM, a British biotechnology company who are
commercialising DARC Technology, developed by Professor M Francesca
Cordeiro through Wellcome Trust funding.
DARC technology is a new exploratory biomarker for use in glaucoma &
AMD clinical studies.
DARC combines an innovative patented biologic with a
state-of-the-art AI algorithm. For the first time in humans, using
standard imaging equipment, DARC is able to identify cellular level
DARC can de-risk clinical development, improving study outcomes
whilst reducing time to market and costs for glaucoma and AMD
InveniAI is a technology company that has pioneered the application
of artificial intelligence (AI) and machine learning (ML) to
transform innovation across healthcare and other industries.
Our flagship platform, AlphaMeld, was designed on the premise that
every innovation begins with a core discovery or invention that
Numerous industry collaborations with big pharma, specialty pharma,
biopharma, and consumer healthcare showcase the value of our
platform in recognizing complex patterns and associations that
represent the earliest signals of innovation.
JoVE is a productivity and training platform for pharmaceutical and
biotechnology companies creating innovative new medicines and cures.
With JoVE’s clearly visualized cutting-edge experiments with
peer-reviewed video articles, corporate scientists will:
|– Increase productivity in the lab,|
– Streamline training processes,
|– Learn emerging techniques and technologies,|
|– Skip avoidable experimental errors,|
|– Get results faster and beat R&D deadlines.|
Headquartered in Cambridge, Massachusetts, JoVE also maintains
offices in the United States, Europe, India, and Australia. Please
visit www.jove.com/biopharma to learn more.
Blood loss is the leading cause of preventable death after trauma.
KaloCyte, Inc., a preclinical biotech startup, has demonstrated
proof of concept for ErythroMer, a dried, bio-inspired artificial
red blood cell, to treat life-threatening hemorrhage when stored
blood is not an available option. This nano-encapsulated human
hemoglobin mimics RBC physiology and is a highly efficient oxygen
carrier. Its synthetic polymer shell makes it a universal option for
all blood types. It can be freeze-dried for long-term storage
without refrigeration, and quickly reconstituted for rapid
administration when needed – potentially saving thousands of lives
in pre-hospital settings.
ktMINE collects, organizes, and connects transactional and
Intellectual Property (patents, trademarks, agreements, royalty
rates, etc.) data to help you quickly and confidently perform
research. ktMINE then takes that data and turns it into real,
With ktMINE, quickly develop, value and create tactics to execute an
IP transaction strategy using a single tool. We support your IP
research, analysis and decision-making process with the ability to
investigate competitors, technologies, patents and other
intelligence to foster your IP transaction strategy, maximize your
IP asset strategy by leveraging data to drive commercialization &
monetization agreements and much more.
|Company:||Latham BioPharm Group|
Latham BioPharm Group provides the insight, knowledge, and network
to unite teams and technologies in the Life Sciences. We provide the
depth of expertise necessary to advance programs, by offering a
range of life science services including business development,
program management, functional subject matter expertise and
strategic consulting; with proven experience in biodefense/pandemic
response and strategic product development.
We assist clients in evaluating critical business decisions and
connecting with the target markets to assess opportunities. We
assist in finding and securing funding. We then drive successful
advancement to a targeted value-inflection point and help monetize
LAT Research is a privately-owned full-service CRO company which
operates in Latin American countries with staff dedicated to all
aspects of Regulatory Affairs, Strategic Planning, Clinical
Research, Medical Writing, Biostatistics and Pharmacovigilance. LAT
was created in 2010 to conduct the first full-scale clinical trial
in the setting of Chagas Disease in pediatric population. Since
then, our staff have been involved in 50 different studies, 26 of
them fully conducted enrolling more than 6,600 patients in different
therapeutic areas. Particularly in neglected diseases, LAT is the
more experienced organization in conducting clinical trials in
LATAM. Solid experience in helping companies to reach the goals for
priority review vouchers in neglected or tropical diseases, rare
disease or pediatric indications based on qualified staff and access
to target population.
|Ticker Symbol & Exchange:||ASX: LBT|
LBT Innovations is an Australian medical technology company using AI
to deliver automation in healthcare. The company has developed a
patent protected, machine learning and intelligent imaging platform
technology to deliver the only FDA Class II cleared instrument
utilizing AI technology in clinical microbiology.
The APAS® Independence automates the imaging, image analysis,
LBT Innovations is exploring opportunities to extend our platform
technology towards new healthcare applications requiring
cutting-edge computer vision and analysis.
Leuven MindGate represents the ecosystem of Leuven, a knowledge
region at the pinnacle of Health, High-Tech and Creativity, an ideal
place for companies and talented people.
LifeNet Health is a leading global provider of human transplant,
tissue allografts, and regenerative medicine solutions, driven by
our mission of saving lives, restoring health and giving hope. The
LifeSciences Division is dedicated to providing researchers with a
broad spectrum of services to drive human tissue and cell-based
discovery. Our resources and services include:
Human primary cells including hepatocytes and islets, biospecimens
for research, and a fully human 3D microtumor oncology assay system.
To learn more, contact us by email at
firstname.lastname@example.org or by phone at 757-464-4761.
|Company:||LMK Clinical Research Consulting|
Inspection Readiness. Two words that can ignite worry, fear, and
stress. At LMK, we work with our clients to alleviate those concerns
and ensure that you are inspection ready from Day One. We believe
that the clinical trial content is the foundation of every clinical
trial, and a strong foundation is key to the overall health and
stability of any clinical program. We offer our clients a
combination of expertise, tools, processes, and extensive knowledge
of the clinical drug development process. Our experts will assess
your study requirements and processes and create a plan customized
to meet your specific needs.
ManagedLab Services is a Certified Women Owned Small Business,
leading the life science industry in Lab Support, Vendor Managed
Inventory, and Project Management for U.S. based labs of all sizes,
from startup through large pharma.
We combine top-notch customer service with our expertise in best
practices for Laboratory Operations and overlay that with
cutting-edge automation to give you the most efficient lab available.
Our unique combination of highly trained PEOPLE, documented
PROCESSes, and reportable DATA ensures your lab is always
Our vendor agnostic approach allows us to support all products, from
all suppliers, giving you the FREEDOM OF CHOICE.
|Company:||Mazars USA LLP|
Mazars USA LLP is a high-performing accounting, tax and consulting
firm with significant national presence in strategic US geographies.
Since 1921, our dedicated professionals have leveraged technical
industry expertise to develop customized solutions for clients,
create value, and optimize their performance. We offer a broad array
of industry specialists providing services to growth-oriented
enterprises and individuals. As the independent US member firm of
Mazars Group, we deliver seamless access to the expertise of 23,000
professionals in 89 countries. At local and global levels, we are
proud of our value-added services, building lasting relationships
with our clients and communities. For more information, visit us at
|Company:||Meridian BioGroup LLC|
Meridian BioGroup is a Maryland-based service provider and
consultancy to FDA-regulated pharmaceutical and biopharmaceutical
companies, government institutes and academic institutions in the
areas of Quality, Validation and Regulatory Affairs. Established in
2007, Meridian currently employs 30 skilled professionals and eight
subcontracted partners, with a combined 400+ years of experience in
GXP (cGMP, GLP, GTP), CLIA and ISO and backgrounds in manufacturing,
quality control, quality assurance, regulatory affairs, engineering,
validation, and document control. We have experience in
pharmaceuticals, biologics, medical devices, biosimilars, and
combination products and extensive expertise with multi-product and
contract manufacturing facilities, contract testing operations, and
|Company:||National Taiwan Ocean University GLORIA|
The NTOU GLORIA serves as a platform further bridging the academia
and industry sectors through forming a strong alliance with
resources from both sectors and assets from NTOU’s resourceful
alumni and partner research institutes. The GLORIA provides
customized services to the industrial partners to meet their
specific needs to grow business. GLORIA focuses on advanced
aquaculture technology fields.
We build Industry-University-Institute platforms in order to link
Taiwan with the global market.
|We also provide industry consultant and scientific research services.|
Nuventra is a group of pharmaceutical scientists that partner as
virtual extensions of our clients’ teams. We focus on helping
companies avoid costly missteps in their development programs and
can increase their chances for regulatory authorization.
Specializing in nonclinical and clinical pharmacology,
pharmacokinetics, pharmacodynamics and modeling and simulation, our
consultants bring their 10-30 years of experience to advise on next
We can come on board as early as candidate selection and work
alongside through clinical studies. Our team can help identify risks
and the strategies to mitigate them.
We enable drug developers and investors to make better strategic
decisions. Our ability to translate complex PK/PD data into
actionable insights to inform development and investment decisions
is what makes us unique.
|Booth:||4270 – IZ-29|
Oligomerix is an early-stage biotechnology company focused on
discovering and developing novel, small-molecule tau oligomer
inhibitors for Alzheimer’s disease (AD) and related
neurodegenerative diseases with tau pathology. Oligomerix’ drug
discovery platform has identified a pipeline of novel, central
nervous system (CNS) small molecule lead compounds designed to
inhibit tau oligomer formation at the beginning of the aggregation
process. The company’s lead program targeting AD has initiated
IND-enabling studies. The NYC based company is located at the
Ullmann Research Center for Health Sciences within the Albert
Einstein College of Medicine and has received considerable support
from the National Institute of Health (NIH). Oligomerix is seeking
strategic partners to support the acceleration and advancement of
these important programs. For more information about Oligomerix,
please visit www.oligomerix.com.
|Company:||Ology Bioservices, Inc.|
Ology Bioservices is a biologics-focused Contract Development
Manufacturing Organization (CDMO) serving both government and
commercial clients from early stage through commercial product. The
company has 183,000 square feet of manufacturing, process
development, and quality assurance/quality control space in its
state-of-the-art facility in Alachua, FL; and an analytical,
bioanalytical, & cell-line development and testing laboratory in
Berkeley, CA. The experienced team at Ology Bio provides support in
upstream & downstream process development, formulation & analytical
development, and cGMP manufacturing of mAbs, recombinant proteins,
live viral products, nucleic acids, and cell & gene therapies up to
BioSafety Level 3 (BSL-3). The company also offers full regulatory
support from preclinical through licensure from its Frederick, MD
|Company:||Ompi – Stevanato Group|
Founded in 1949, Stevanato Group is committed to creating systems,
processes, and services that guarantee the integrity of parenteral
It comprises two operational divisions dedicated to serving the
pharmaceutical and healthcare industry: The Pharmaceutical Systems
Division, specialized in glass primary packaging, – through Ompi –
specialty plastics and delivery devices, and the Engineering Systems
Division dedicated to assembly and packaging solutions, as well as
reliable inspection systems. The Group also benefits from SG Lab
activity that provides technical and analytical services to ensure
drug’s integrity and device’s injection performance.
|Company:||Oxford Brain Diagnostics Ltd.|
Oxford Brain Diagnostics, a spinout from the University of Oxford,
has developed a novel approach (Cortical Disarray Measurement – CDM)
for extracting correlates of micro-anatomy from standard MRI brain
images, providing valuable information about Alzheimer’s disease
(paper under review). The past eight years has seen the
collaboration of two world class specialists – Dr Steven Chance
(CEO), Neuroscience and Pathology and Professor Mark Jenkinson
In unpublished tests, CDM has been used to classify which patients
will develop Alzheimer’s and other forms of dementia within 2 – 3
years. Early results indicate promising outcomes for differential
diagnosis between dementias.
|Company:||PARAS BIOPHARMACEUTICALS FINLAND OY|
Paras Biopharmaceuticals is a Finland-based Biopharmaceutical
company. We offer Microbial CDMO services, Biosimilars & Biologics,
and Bioprocess enzymes.
-Microbial CDMO for the production of Fusion Proteins scFv, Complex
Biologics, Nanobodies, Diabodies
-Biologics & Biosimilars – Recombinant Teriparatide, Recombinant
Anakinra (Kineret® Biosimilar), Recombinant Rasburicase and
Recombinant Romiplostim (N-plate® Biosimilar).
|-Bioprocess Enzymes – Recombinant TEV and Enterokinase.|
Paras Biopharmaceuticals has a fully equipped microbial production
facility in Finland, for the production of recombinant therapeutic
Please refer to our website www.parasbiopharma.com for further
PharmaEssentia Corp. is a fully integrated global biopharmaceutical
company headquartered in Taipei, Taiwan. It was established by a
group of highly accomplished scientists from leading pharmaceutical
companies, and led by seasoned executives with 100+ years of
experience at biotechnology and regulatory agencies. The company
aims to deliver efficacious, safe, and cost-effective therapeutic
products to treat human disease, while bringing long lasting value
Ropeginterferon alfa-2b is a novel, mono-pegylated proline
interferon alfa-2b invented by PharmaEssentia and manufactured at
its own biologics facility in Taichung, Taiwan. The biologics
facility had been certified by Taiwan Food and Drug Administration
and European Medicines Agency, and is also designed and operated to
be compliant with US FDA requirements.
|Company:||PMI BioPharma Solutions|
Located in Nashville, TN, PMI Bio provides high throughput library
screens and designs, develops and tests drugs in vitro and in vivo
using relevant cell lines and murine models. Our research scientist
also express and purify proteins and develop assays around protein
targets using NMR, SPR, crystallography, ITC, TR-FRET, and DSF to
name a few. We even have a vivarium with mice and rats bred
specifically for search supporting immunology, wound healing, cancer
research, genetics, diabetes and toxicology. PMI can also provide
you with aseptic and non-aseptic clinical trial materials.
|Ticker Symbol & Exchange:||QTRX NASDAQ|
Quanterix is a company that is digitizing biomarker analysis with
the goal of advancing the science of precision health and
dramatically changing the way healthcare is provided. Our two
ultra-sensitive technology platforms, Simoa® Bead and Simoa Planar
Array, give researchers the ability to quantify biomarkers for a
range of diseases at lower levels than ever before, in most common
sample types. Simoa’s ultra-sensitivity, multiplex detection
capability and flexibility in custom assay development are advancing
academic research and helping to accelerate drug development and
approval, both in our customers’ own facilities and by contract in
our CLIA-certified Quanterix Accelerator Laboratory.
|Company:||Queensland University of Technology|
Queensland University of Technology (QUT) is a major Australian
university internationally recognised as a provider of high-impact
medical and agricultural biotechnology research delivered through:
The Institute of Health and Biomedical Innovation (IHBI), a
multidisciplinary research institute devoted to improving the health
of individuals and communities through research innovation. IHBI has
world leading expertise in areas of prostate cancer, infectious
diseases, burns and wound management, genomics, orthopaedics and
trauma, vision, medical robotics and devices and biofabrication.
The Centre for Tropical Crops and Biocommodities, brings together
|Company:||Random42 Scientific Communication|
Random42 is the global leader in providing digital scientific
communication solutions to the pharmaceutical and biotechnology
industry. We bring challenging medical and scientific concepts to
life, making them simple, beautiful and easy to digest.
|• Medical Animation|
|• Scientific Virtual Reality|
|• Augmented Reality|
|• Interactive Touchscreens|
|• Interactive Experiences and Applications|
|• Booth Design and Exhibition Experiences|
|• Web and Print|
With over 27 years’ experience, we have grown into the largest
company within the industry and have won over 175 awards for our
high-quality medical animation and scientific storytelling – a clear
Recro Gainesville provides oral solid dosage form development,
clinical and commercial manufacturing, and packaging services to the
global pharmaceutical market. Specializing in modified release
formulations and DEA controlled substances, Recro has the experts to
deliver clients’ most complex pharmaceutical development and
manufacturing projects in its best-in-class, 120,000 square feet of
manufacturing space. For more information about Recro’s flexible
CDMO solutions, visit www.recrogainesville.com.
Rockville Economic Development, Inc.
Rockville Economic Development, Inc. (REDI) assists businesses
locate and grow in the City of Rockville, Maryland, which is part of
the larger Washington DC Metro area. Rockville offers a family
friendly community, top schools, and lower real estate prices than
many neighboring communities in the Washington DC area. The area is
one of the strongest BioHealth ecosystems in the United States, with
proximity to the National Institutes of Health, Federal Drug
Administration, John Hopkins University and the University of
Maryland. For more information contact us at email@example.com.
|Ticker Symbol & Exchange:||4201, Tokyo Stock Exchange|
BioProduction by Sekisui offers contract development and
manufacturing services for the biopharmaceutical industry. Our
facility in the UK has over 40 years of large scale fermentation and
purification experience. We offer expertise in bioprocess
development, scale up and manufacturing of enzymes, plasmids, and
other proteins for use in the production of biopharmaceuticals. We
offer GLP, ISO 13485 and GMP manufacturing.
|Company:||SINOPEG BIOTECH CO., LTD|
SINOPEG makes high-quality PEG products for therapeutic protein
drugs, medical devices (hydrogel and coatings). Our company serves
pharmaceutical and medical device companies around the globe, with
product presence in various pharmaceutical/device development
pipelines (pre-clinical, clinical, and post authorization large
Our facility is ISO9001 and ISO13485 certified (primarily for GMP
requirement of medical devices), and operates according to ICH GMP
guidelines to produce products for pharmaceutical companies.
Since its inception, SINOPEG has partnered with different stage
pharmaceutical companies and provided pegylation products, PEG
hydrogels, block polymers and liposomes.
|Company:||Site Selection Magazine/Conway Inc.|
For over 65 years Site Selection magazine has been the top-rated and
most respected publication covering foreign direct investment (FDI),
airport cities and global corporate real estate. Site Selection –
winner of the MAGS/GAMMA Gold Award for Best Business to Business
Publication – provides exclusive insight into strategies, real
estate markets, relocation costs and available incentive programs –
in short, the key factors involved in corporate facility planning.
Site Selection’s parent company, Conway Data, offers a host of lead
generation services across the world.
The FDA has advised in its 2014 Guidance for Industry that “It is
Synova is a Full Service Contract Research Organization based out of
Brazil, stemming from the country’s population pool of 200 million.
We are the largest CRO in Latin America, born out of the Brazilian
Bioequivalence Center CAEP, and have become the “Go To” solution in
the Pharma/Biotech and devices Industries.
Thetis is developing a potential first-in-class, safe, oral therapy
for the treatment of inflammatory bowel disease (IBD), a set of
chronic, relapsing gastrointestinal inflammatory disorders that
includes ulcerative colitis and Crohn’s Disease.
|Company:||Two Labs – Pennside Partners|
For over 25 years Two Labs – Pennside Partners has assisted
pharmaceutical companies and investors to identify promising
candidates for in-license/investment. Using this experience, we have
developed a service for emerging biotechnology companies to optimize
positioning and messaging when seeking partnerships and investment.
Pennside Partners uses primary research along with robust
proprietary databases to ensure our clients are up to date on the
current and future treatment landscapes. Utilizing experts such as
former BD&L Managers from Major Pharma/Biotech companies, we provide
best-in-class partnering support for small pharma/biotech and
|Stop by booth 4063 to learn more at BIO 2019.|
|Company:||Validation & Engineering Group|
Validation & Engineering Group (V&EG) provides world-class service
to the Biotechnology, Pharmaceutical, Medical Devices, Chemicals
(API), Food, and Cosmetics industries.
For more than 20 years V&EG has placed talented professionals in a
position to make a difference in our customer’s success. The
technical experience and expertise of our staff, comprised of more
than 140 professionals from the engineering and sciences fields,
keeps us among the top firms in the industries we serve.
Our services platform is split into: Regulatory Compliance,
Validation and Qualification, Laboratory (Validation, Audits), and
Engineering (Design Qualification Services), that ensure adherence
to Federal and European regulatory agencies.
VGXI, Inc. is a leading contract manufacturer of DNA based
pharmaceuticals with over 15 years experience providing exceptional
quality cGMP products to clinical trials worldwide. The company’s
skilled team has an outstanding track record of success in
manufacturing challenging plasmid products under cGMP conditions
with exceptional yield, quality, and prompt delivery. Production
services include high purity plasmid DNA preparations for
pre-clinical research, Highly Documented (HD) plasmid DNA
manufacturing for use in pharmacology / toxicology studies or GMP
viral vector production, and cGMP plasmid DNA for clinical through
Vibalogics is a Contract Development and Manufacturing Organisation
(CDMO) offering process development, cGMP manufacturing and
fill/finish of products based on viruses and live bacteria for
companies developing products used as gene and oncolytic viral
therapies and vaccines. With services including feasibility
assessment, technology transfer, process development, cGMP
manufacturing, formulation/blending, fill/finish (liquid and
lyophilized), QC analysis and Product release, Vibalogics offers a
full range of development and manufacturing services, underpinned by
excellent quality and a transparent customer experience. Established
over fifteen years ago, Vibalogics has a proven track record and is
one of the leading players in live biological manufacturing.
Vistara Bioscience is developing proteomics processes and
bioinformatics for detecting networks of proteins and accessory
factors which are in close collaboration with proteins of clinical
interest. The networks serve as biomarker panels to follow along the
drug discovery process, and additionally, may suggest combinatorial
targets or new ones. Vistara expects to offer Services to pharma and
biotech partners for drug discovery, candidate profiling, and
molecular phenotyping applications with initial focus in Oncology,
Infectious Diseases and CNS disease areas.
We are a multi-disciplinary communications design firm with 25+
years of experience partnering with companies to define their story,
structure their brand, and inspire their audience. We are
media-agnostic and are focused on communicating your company’s story
clearly and effectively across every messaging platform.
For over 25 years we’ve succeeded in helping our clients to grow and
are honored to be a valued partner for some of the most innovative
and successful companies in the world. Our narrative-first approach
unifies corporate, investor and employee communications to build
brand communications systems that are robust for today’s challenges
and extensible for tomorrow’s opportunities.
Agritek Holdings, Inc. Announces Proposed Completion Date of Apex Extractions Acquisition Including Assets, Brands and Distribution Into Wholly Owned Subsidiary
LOS ANGELES, CA, Jan. 22, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Agritek Holdings, Inc. (AGTK) www.AgritekHoldings.com, a fully integrated, active real estate investor for the cannabis sector and consultant for multiple cannabis brands, today announced that the Company expects to complete the acquisition of certain assets of Apex Extractions including brands and distribution licenses into a wholly owned subsidiary of Agritek Holdings by February 2020. Apex is a California based licensed manufacturer and distributor of over eleven Cannabis Cup award-winning brands (www.Apexextractions.com).
The highly anticipated acquisition brings together one of the most recognized cannabis brands in California with licensed manufacturing facilities in Oakland, California as a wholly owned subsidiary with immediate access to the public markets. Agritek Holdings is presently applying for a name change post acquisition to reflect the company’s pure real estate holdings model as Apex will represent the cannabis brands, assets, revenue and distribution model as the subsidiary. Both Companies will benefit investors strategically with the “new” Agritek Holdings seeking to purchase and lease back additional industrial zoned and innovative properties for cannabis operators with Apex and its partners acting as tenants and licensee’s for manufacturing, retail and cultivation operations in multiple legal jurisdictions.
“Under our new proposed acquisition structure, Apex will continue to provide manufacturing and distribution of our leading brands initially in California with revenue flowing through our subsidiary as Agritek, our parent and holding company will act as our real estate partner funding operations as we expand to multiple jurisdictions creating a perfect synergy for the sector,” stated Scott Benson, CEO of Agritek Holdings.
Approval of the executed definitive agreement and asset acquisition and name change is subject to the standard due diligence process and compliance for transactions approved for trading by OTC Markets.
About Agritek Holdings, Inc.
Agritek Holdings, Inc. (www.AgritekHoldings.com), is a fully integrated, active real estate investor and advisor in the legal cannabis sector. Specifically, Agritek Holdings provides strategic capital and functional expertise to accelerate the commercialization of its diversified portfolio of cannabis related holdings. Currently, the Company is focused on three high-value segments of the cannabis market, including real estate investment, intellectual property/brands, and infrastructure, with operations in three U.S. States, Canada, and Puerto Rico. Agritek Holdings, Inc. presently owns or manages cannabis properties in Colorado, Puerto Rico and Canada and has licenses with permitted facilities in California approved for cultivation as well as manufacturing capabilities. The company owns several Hemp and cannabis brands for distribution including “Hemp Pops”, Hemp oil wellness products, “Higher Society” and “California Premiums”. Agritek Holdings Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act.
About Apex Extractions
Founded in February 2017, Apex Solutions was one of the first licensed, recreational cannabis manufacturers established when legalization occurred in the state of California. So far in 2019, Apex Extractions’ concentrates and pens have already won 10 High Times Cannabis Cup awards and last month the company introduced the Apex Solutions Fresh Club subscription delivery service. Apex additionally provides bulk concentrates to some of the largest brands in California.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Agritek Holdings, Inc. to be materially different from the statements made herein.
Agritek Holdings, Inc.
SpeakEasy Cannabis Club Ltd Reveals Strategic Direction For 2020
SpeakEasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the “Company” or “SpeakEasy“), a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act, today revealed its plans to transform into a global cannabis brand by applying large scale commercial farming principles to burgeoning national and international markets. Building on the Geen family’s 100 years of experience farming cherries, apples, ginseng and peaches, the Company plans to cultivate small batch, high quality craft cannabis and, subject to receipt of all applicable licences from Health Canada, produce approximately 70,000kg of outdoor sun-grown cannabis in 2020.
The Company expects that in 2020 there will be a shift in the global cannabis industry into a consumer-packaged goods industry with the introduction of new product categories and increased segmentation in existing ones. SpeakEasy has developed a business model that adds core value and amplifies brand differentiation in what is expected to be a flourishing market. Building on its solid foundation, the Company will identify international revenue sources and replicate its operations in emerging global cannabis markets.
Moving from speculation to reality, a correction in the industry has taken place as dissatisfaction with current product offerings impacts sales projections. By focusing on both indoor and outdoor cultivation and following the proven business frameworks of successful multinational farming cooperatives, SpeakEasy is positioned to cultivate premium BC cannabis and deliver significant revenues and cost efficiencies.
“The blueprint to agricultural success must begin with proper site selection. It is the foundation of all farming,” says SpeakEasy Founder, Marc Geen. “As a fourth generation farmer benefitting from the Okanagan’s fertile golden mile, we have an intrinsic understanding of the land and how to cultivate and grow.”
Indoor cultivation: SpeakEasy completed the construction of its 10,000 sq. ft. purpose built indoor facility in November 2019, bringing its total indoor growing space, once all the buildings are completed, to approximately 63,000 sq. ft. SpeakEasy applies craft cultivation techniques to grow premium craft cannabis in this space. To target the luxury cannabis market large corporations have started to invest in small batch producers, for instance Aphria purchased B.C company Broken Coast for $230m. With legacy growers benefitting from over 100 years of combined experience, SpeakEasy is well positioned to produce high margin small batch cannabis.
SpeakEasy founder Marc Geen says, “We don’t need to look far to see what happens in a mature cannabis market, high quality, actual high quality becomes the norm and sells well, mid or low quality simply does not sell. SpeakEasy is fixated on producing the best quality possible in our purpose built tried and true facilities.”
Outdoor cultivation: SpeakEasy projects that delivering cost efficiencies will be essential as cannabis transforms into a global consumer packaged goods industry. The Company projects that outdoor cultivation will enable it to produce trimmed flower for approximately $0.04 per gram and biomass for extraction at approximately $0.02 per gram. The Company has recently built an outdoor facility and has applied for an outdoor cultivation licence, which it anticipates receiving in Q1 2020.
CBD hemp plantation: SpeakEasy expects to plant a minimum of 50 acres of hemp in 2020 in an outdoor field, that was fully prepared in the fall of 2019. By controlling input costs by producing their own hemp, coupled with innovative extraction methods, SpeakEasy projects its cost to produce a 80% CBD distillate to be under $1,000/kg versus current prices that can run as high as $30,000/kg, allowing the Company to enter global markets at a competitive price.
Consumer facing brands: SpeakEasy is building real brands for the future with the development of multiple consumer products, including high THC flower, medical cannabis and CBD products. SpeakEasy believes that to succeed in the competitive cannabis market, brands must be developed authentically to engage and resonate with consumers. By harnessing legacy growers and an extensive library of unique genetics, the Company will be able to produce high quality small batch cannabis indoors and exceptionally low cost flower for extraction purposes outdoors.
Online sales: Domestic cannabis markets have been restricted by availability and supply chain issues. To meet the needs of the modern consumer and improve supply chain resilience, SpeakEasy has undertaken projects to become vertically integrated through BWell – the first CBD e-commerce marketplace in Canada. The initiative will enable the Company to acquire new customers at a low cost and expand upon a business model that mirrors Amazon’s marketplace approach. Management expects that this marketplace approach will advance SpeakEasy’s aim to become a recognized household name across North America.
Extraction processing: The introduction of new product categories has the potential to add significant revenue streams for companies with extraction capabilities. To capitalize on this opportunity SpeakEasy is developing a state-of-the art 26,000 sq. ft. extraction facility, which it expects to complete in Q3 2020. Once in service, the Company expects to augment operations by processing up to 350,000kg of cannabis annually.
2020 Timeline of Project Completion Dates:
Q1 – Outdoor License Amendment, Hemp Field License & First Harvest
Q2 – Outdoor Planted, Hemp Fields Planted
Q3 – Extraction/Processing & Cooler Building
Q4 – Product on shelves
“We started out differently than most by beginning everything we do with the simple question, what do our customers want, and we built everything with that in mind. Consumer wants and needs cannot be an afterthought or something we figure out later, it is the sole purpose for everything we do,” says Founder, Marc Geen. “Quality, genetics, product types and pricing all need to make a formula that works to supply our customers. SpeakEasy has never been a stock play, it has always been a business built from the ground up with a long bright future in front of it.”
SOURCE Speakeasy Cannabis Club Ltd.
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that it has appointed Larry Kaiser, MD, FACS to its Board of Directors, effective immediately. Dr. Kaiser will also continue to serve as the Chairman of FSD Pharma’s Scientific Advisory Board (SAB).
Dr. Kaiser is currently the Managing Director with the Healthcare Industry Group at Alvarez and Marsal, a leading global professional services firm. Most recently, Dr. Kaiser was the President and CEO of the $2.2 billion Temple University Health System (“Temple”), Dean of Temple University’s Lewis Katz School of Medicine, and Senior Executive Vice President for Health Sciences at Temple University. Among his many accomplishments at Temple was the acquisition of the Fox Chase NCI-designated Comprehensive Cancer Center, the development of a number of programs, including the number one lung transplant program in the country, a nationally recognized program in pulmonary hypertension, in addition to growing programs in cardiovascular surgery, thoracic surgery, neurosurgery, and orthopedic surgery. Before joining Temple University in 2011, Dr. Kaiser served as the President of the University of Texas Health Science Center at Houston, the largest of six health-related campuses at the University of Texas.
“With decades of academic and senior executive experience in medicine and the delivery of healthcare in the United States, Dr. Kaiser brings substantial depth and strength to our Board of Directors,” said Raza Bokhari, MD, Executive Co-Chairman and CEO of FSD Pharma. “Dr. Kaiser has already contributed immensely as Chairman of our world-class Scientific Advisory Board, where his input has been very meaningful in shaping our Biosciences strategy to focus on assembling synthetic compounds that target the CB2 receptors of the endocannabinoid system of the human body. As a Director, we are relying on his leadership and sage counsel as we continue to double down on our Biosciences effort to eventually bring to market prescription-based drugs by conducting rigorous FDA-approved clinical trials.”
Dr. Kaiser stated, “I am truly honored to join the outstanding leadership group that Dr. Bokhari has assembled at FSD Pharma. I am impressed with the entrepreneurial spirit that this company brings and look forward to a number of exciting developments in the months to come. It is a privilege to work with a group so committed to building a successful and innovative company based on the foundation created by its founders.”
Dr. Kaiser graduated AOA (Alpha Omega Alpha Honor Medical Fraternity) from the Tulane University School of Medicine in 1977 and completed his residency in general surgery as well as a fellowship in surgical oncology at the University of California, Los Angeles. He then completed a residency in cardiovascular and thoracic surgery at the University of Toronto. Following that, he held positions as attending thoracic surgeon at Memorial Sloan-Kettering Cancer Center and Assistant Professor of Surgery at Cornell University Medical College (both New York City) and subsequently as Associate Professor (with tenure) at the Washington University School of Medicine (St. Louis). At the University of Pennsylvania, Dr. Kaiser held a variety of positions, including chief of general thoracic surgery, founder and director of the university’s lung transplantation program, director of its Center for Lung Cancers and Related Disorders, and co-director of the Thoracic Oncology Laboratory. In 2001, following a national search, he was named the John Rhea Barton Professor and Chair of the Department of Surgery as well as Surgeon in Chief for the University of Pennsylvania Health System. In 1997, Dr. Kaiser was named as the first recipient of the Eldridge Eliason Professorship of Surgery endowment at the Perelman School of Medicine at the University of Pennsylvania.
Dr. Kaiser is author or co-author of 17 books and more than 300 original papers, and he serves on multiple editorial boards, including the Annals of Surgery, the world’s leading surgical journal, the American Journal of Surgery, and the European Journal of Cardiothoracic Surgery. Dr. Kaiser has served in a number of leadership capacities for professional societies and associations and has been a director of both the American Board of Surgery and the American Board of Thoracic Surgery. In 2005, he was elected to the National Academy of Medicine.
SOURCE FSD Pharma Inc.
Cannabis3 weeks ago
Flora Enters Into Agreement to Acquire Kasa Wholefoods Company S.A.S.
Cannabis3 weeks ago
HEXO CORP. INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against HEXO Corp.
Cannabis4 weeks ago
Hemp, Inc. CEO, Bruce Perlowin, Featured In Havasu News Coverage About Kins Communities
Cannabis3 weeks ago
Top Strike Announces 2020 Second Quarter Financial Results and Provides Corporate Activity and Update
Cannabis3 weeks ago
MediPharm Labs Receives Licence Amendment to Permit Use of Expanded Canadian Facility for Private Label and White Label Production and R&D
Cannabis2 weeks ago
Hightimes Holding Corp. names former Overstock.com President as new CEO as it readies itself for Commerce
Cannabis4 weeks ago
HEXO CORP. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against HEXO Corp.
Cannabis3 weeks ago
Hemp, Inc. Applauds USDA’s New Insurance Option For Hemp